Overview
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Status:
Completed
Completed
Trial end date:
2009-08-01
2009-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
PfizerTreatments:
Fesoterodine
Warfarin
Criteria
Inclusion Criteria:- Healthy male and/or female subjects between the ages of 18 and 55 years
Exclusion Criteria:
- Not healthy subjects--subjects with acute or chronic medical or psychiatric conditions
or laboratory abnormality